RE:RE:RE:Results are out on SedarQuarter to quarter post launch revenue of a drug is a critical measure of consumer acceptance. Especially if it takes a couple of months to be effective. Its a little early to know how 1067 is doing in the marketplace, given that R + F ordered initial stock prior to launch and the dark spot corrector was launched mid March, with a tube lasting a long time in its current format and indication for spot therapy only. Cash reserves are low however and unless some big repeat orders are in place nownor another deal is on the short term, SBM will haemorrhage.